Meeting
2024 ASCO Gastrointestinal Cancers Symposium
The overall safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma.
Authors
Kazuhiro Shiraishi
National Cancer Center Hospital, Chuo-Ku, Tokyo-to, Japan
Kazuhiro Shiraishi , Shun Yamamoto , Yuri Yoshinami , Akihiro Ohara , Mai Itoyama , Kazuki Yokoyama , Yoshitaka Honma , Tairo Kashiraha , Daisuke Kurita , Koshiro Ishiyama , Junya Oguma , Hiroshi Igaki , Hiroyuki Daiko , Ken Kato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 329)
DOI
10.1200/JCO.2024.42.3_suppl.329
Abstract #
329
Poster Bd #
F9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
First Author: Ian Chau
Poster
2024 ASCO Annual Meeting
First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment.
First Author: Michael A. Postow
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.
First Author: David James Pinato
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.
First Author: Kunihiro Fushiki